Cover Image
市場調查報告書

急性淋巴性白血病 (ALL):全球臨床實驗趨勢

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017

出版商 GlobalData 商品編碼 212837
出版日期 內容資訊 英文 1007 Pages
訂單完成後即時交付
價格
Back to Top
急性淋巴性白血病 (ALL):全球臨床實驗趨勢 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017
出版日期: 2017年02月28日 內容資訊: 英文 1007 Pages
簡介

本報告提供急性淋巴性白血病 (ALL) 治療藥相關臨床實驗最新趨勢相關分析,以疾病概要為首,提供G7各國·E7各國的臨床實驗狀況,各地區、各階段的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要5國的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:癌症治療藥臨床實驗上急性淋巴性白血病 (ALL)的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:癌症治療藥臨床實驗上急性淋巴性白血病 (ALL)的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

急性淋巴性白血病 (ALL) 治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4079CTIDB

GlobalData's clinical trial report, "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2017" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 18
  • Clinical Trials in G7 Countries by Trial Status 19
  • Clinical Trials by E7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 21
  • Clinical Trials by Phase in E7 Countries 22
  • Clinical Trials in E7 Countries by Trial Status 23
  • Clinical Trials by Phase 24
  • In Progress Trials by Phase 25
  • Clinical Trials by Trial Status 26
  • Clinical Trials by End Point Status 27
  • Subjects Recruited Over a Period of Time 28
  • Clinical Trials by Sponsor Type 29
  • Prominent Sponsors 30
  • Top Companies Participating in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials 32
  • Prominent Drugs 34
  • Latest Clinical Trials News on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) 35
  • Feb 23, 2017: Children's National Health System Experts Present Data on Novel Approach to Cell Therapy for Cancer Patients 35
  • Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing "Point-of-Care" Approach 35
  • Jan 09, 2017: Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China 36
  • Dec 22, 2016: Immunomedics Awarded Additional Intellectual Property Protection for IMMU-140, an Antibody-Drug Conjugate With Dual-Therapeutic Potential 36
  • Dec 19, 2016: Kancera reports positive results for fractalkine blocker KAN0440567 in preclinical models of pain caused by anti-cancer drugs 37
  • Dec 06, 2016: Juno Therapeutics Presents data on investigational CAR T cell product candidate JCAR017 at 58th American Society of Hematology 37
  • Dec 06, 2016: Juno Therapeutics Presents data on investigational CAR T cell product candidate JCAR-018 at 58th American Society of Hematology 38
  • Dec 06, 2016: Affimed Presents New Preclinical Data on AFM-11 at ASH 39
  • Dec 06, 2016: ARIAD Announces Data Presentations at American Society of Hematology Meeting 39
  • Dec 04, 2016: Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL 40
  • Dec 04, 2016: Kite Pharma Reports 82 Percent of Patients Achieved Complete Remission in Preliminary Analysis from Phase 1 ZUMA-3 and ZUMA-4 Trials of KTE-C19 in Adult and Pediatric Patients with High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia 41
  • Dec 03, 2016: In Clinical Trials, CAR T Cell Immunotherapy Continues to Yield Complete Responses in Children & Young Adults with Relapsed and Refractory Leukemia 41
  • Nov 30, 2016: Amgen Announces Presentation Of New Data In Acute Lymphoblastic Leukemia At ASH 2016 42
  • Nov 29, 2016: Sareum to Present TYK2 Cancer Research Programme at the 2016 AACR-NCI-EORTC International Conference 42
  • Clinical Trial Profile Snapshots 44

Appendix 1002

  • Abbreviations 1002
  • Definitions 1002
  • Research Methodology 1004
  • Secondary Research 1005
  • About GlobalData 1006
  • Contact Us 1006
  • Disclaimer 1006
  • Source 1007

List of Tables

List of Tables

  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2017* 17
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2017* 21
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2017* 24
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 31
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 33
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34

List of Figures

List of Figures

  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 19
  • Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2017* 21
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 32
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 34
  • GlobalData Methodology 1004
Back to Top